Drug Testing Advisory Board (DTAB)
This committee has been terminated effective March 31, 2025.
The Drug Testing Advisory Board (DTAB) shall advise the Assistant Secretary, Substance Abuse and Mental Health Services Administration, based on an ongoing review of the direction, scope, balance, and emphasis of the Agency’s drug testing activities and the drug testing laboratory certification program.
About Drug Testing Advisory Board
The Board shall review the Agency’s program for national laboratory certification for Federal workplace drug testing programs as required by Public Law 100-71 and as described in the Mandatory Guidelines for Federal Workplace Drug Testing Programs. It shall recommend areas for emphasis or de-emphasis, new or changed directions, and mechanisms or approaches for implementing recommendations. Periodically, the Board shall review specific science areas on new drugs of abuse and the methods necessary to detect their presence.
Legislative Authority
Advisory Board Charter
Committee’s Official Designation
Center for Substance Abuse Prevention Drug Testing Advisory Board (CSAP DTAB)
Authority
The Center for Substance Abuse Prevention (CSAP) Drug Testing Advisory Board (DTAB) is authorized by 42 USC § 217a, (Section 222 of the Public Health Service Act), as amended. The CSAP DTAB is governed by the provisions of the Federal Advisory Committee Act, as amended (5 U.S.C. 10).
The CSAP DTAB is also referred to as the DTAB.
Objectives and Scope of Activities
To improve the quality of services for forensic workplace drug testing, assess the science and technology used in drug analyses, improve the quality of related laboratory services and systems for drug testing, generate standards for laboratory certification for federal workplace drug testing programs, and guide national policy in these areas.
Description of Duties
The DTAB provides advice to the Assistant Secretary for Mental Health and Substance Use (Assistant Secretary), SAMHSA, based on an ongoing review of the direction, scope, balance, and emphasis of the agency's drug testing activities and the drug testing National Laboratory Certification Program (NLCP).
The DTAB shall review the NLCP for federal workplace drug testing programs as required by Public Law 100-71 and as described in the Mandatory Guidelines for Federal Workplace Drug Testing Programs. It shall provide an ongoing review of the science, laws, and policies that impact the HHS' drug testing activities, including proposed recommendations for areas of emphasis or de-emphasis and mechanisms that will be most effective for implementing any recommendations.
The DTAB shall periodically review specific scientific areas surrounding new drugs of abuse and the methods necessary to detect their presence.
Agency or Official to Whom the Board Reports
The DTAB provides advice to the Assistant Secretary, based on an ongoing review of the direction, scope, and emphasis of the Agency's drug testing activities and the NLCP.
Support
Management and support services shall be provided by the Division of Workplace Programs (DWP), Center for Substance Abuse Prevention (CSAP), SAMHSA.
Estimated Annual Operating Costs and Staff Years
The estimated annual operating costs for the DTAB, to include travel, meetings, federal staff support, and contracting support, is approximately $415, 483.00 and 1.2 fulltime equivalents.
Designated Federal Officer
The Director, CSAP, shall designate a SAMHSA staff member to serve as the Designated Federal Officer (DFO) of the DTAB. The DFO will approve or call all DTAB meetings and subcommittee meetings, prepare and approve meeting agendas, attend and direct all DTAB meetings and subcommittee meetings, adjourn any meeting when the DFO determines adjournment to be in the public interest, and chair meetings when directed to do so by the official to whom the DTAB reports.
Estimated Number and Frequency of Meetings
The DTAB meetings shall be held approximately four times a year upon request of the Assistant Secretary, or Director of DWP, CSAP. The location of the meetings of the Board shall be subject to the approval of the Director, DWP, CSAP. Meetings shall be open to the public except as determined otherwise by the Secretary, Department of Health and Human Services (HHS) (or the designee), in accordance with the Government in the Sunshine Act (5 U.S.C. 552b(c)) and the Federal Advisory Committee Act. Notice of all meetings shall be given to the public. In the event a portion of a meeting is closed to the public, a report shall be prepared which shall contain, at a minimum, a list of members and their business addresses, the DTAB's functions, dates and places of meetings, and a summary of the DTAB's activities and recommendations made during the fiscal year.
Duration
Continuing.
Termination
Unless renewed by appropriate action, the DTAB will terminate two years from the date the charter is filed.
Membership and Designation
The DTAB shall consist of ten (10) members appointed by the Assistant Secretary. Of the ten (10) members, eight (8) shall be recognized as experts in either analytical forensic toxicology, in specimen collection procedures for regulated drug testing programs, or in interpreting drug testing results; one (1) shall represent users of SAMHSA's certified drug testing laboratories and drug-free workplace programs and processes; and one (1) shall represent individuals tested in federal or federally regulated workplace drug testing programs. These members who are not officers or federal employees (full-time or permanent part-time) of the United States shall serve as Special Government Employees (SGE).
The Assistant Secretary shall appoint non-voting ex officio members, who are officers or employees of the United States. The Assistant Secretary will determine the number of ex officio members on the Board. The individuals appointed should represent a variety of disciplines related to forensic drug testing, such as experience in a forensic drug-testing laboratory, related academic research, toxicological research, the Medical Review Officer (MRO) community, or technical expertise from other government agencies involved with drug testing issues, including military drug testing programs.
The Assistant Secretary shall select either an individual from among the appointed members or an appropriate member of SAMHSA staff to serve as the chairperson. If the chairperson is a member of SAMHSA staff, it will be a non-voting position. The term for the chairperson shall be two years.
A quorum for the conduct of DTAB business is the majority (one more than one-half) of the appointed voting membership.
The term of a voting member of the DTAB shall be four years. A voting member may serve after the expiration of the member's term until a successor has been appointed. If a vacancy occurs in the advisory board among the members, the Assistant Secretary shall make an appointment to fill such vacancy within ninety (90) days from the date the vacancy occurs. Initial appointments shall be made in such a manner as to ensure that the terms of the members do not all expire in the same year. A member who has been appointed for a term of four years may not be reappointed to an advisory committee before two years from the date of expiration of such term.
The DWP, CSAP, SAMHSA shall provide orientation and training for new members of the DTAB and shall also provide them with such information and training as may be appropriate for their effective participation in the functions of the Board.
Subcommittees
Subcommittees may be established with the approval of the Assistant Secretary. The advice/recommendations of a subcommittee must be deliberated by the parent board. A subcommittee may not provide advice or work products directly to the agency. The Department Committee Management Officer will be notified upon establishment of each subcommittee and will be provided information on its name, membership, function, and estimated frequency of meetings.
Recordkeeping
Meetings of the DTAB and its subcommittees will be conducted according to the Federal Advisory Committee Act, other applicable laws and Departmental policies. DTAB and subcommittee records will be handled in accordance with General Records Schedule 6.2 of the Federal Advisory Committee Records or other approved agency records disposition schedule. These records will be available for public inspection and copying, subject to the Freedom of Information Act, 5 U.S.C. 552.
Filing Date
June 25, 2024
Approved
June 14, 2024
________________________________________________
Miriam E. Delphin-Rittmon, Ph.D.
Assistant Secretary for Mental Health and Substance Use
Advisory Board Roster
Lisa S. Davis, M.S.
Social Science Analyst, Senior Toxicology Policy Advisor
Division of Workplace Programs
Center for Substance Abuse Prevention
Substance Abuse and Mental Health Services Administration
Room 16N02C
5600 Fishers Lane
Rockville, MD 20857
lisa.davis@samhsa.hhs.gov
Ronald R. Flegel, B.S., MT(ASCP), M.S.
Director
Division of Workplace Programs
Center for Substance Abuse Prevention
Substance Abuse and Mental Health Services Administration
Room 16N01
5600 Fishers Lane
Rockville, MD 20857
ron.flegel@samhsa.hhs.gov
David A. Engelhart, Ph.D., D-ABFT-FD
OH
Elizabeth “Libby” B. Stuyt, M.D.
CO
David K. Roberts, Ph.D., F-ABFT
OR
E. Lindsey Everson, J.D.
TX
Dawn M. Hahn, M.B.A., M.T. (ASCP), D-ABFT
KS
Bryan Ruggery, MFS, D-ABFT-FT
VA
Michael Grommes, D-ABFT-FD
AZ
Carl Christensen, M.D.
MI
Samantha S. Tolliver, Ph.D.
Washington DC
Bonnie A. Droter
Washington, DC
Brian Zaleski
Specialist – Fitness for Duty/Access Authorization
Office of Nuclear Security and Incident Response
U.S. Nuclear Regulatory Commission
Mail Stop OWF-02H07
Washington, DC 20555-0001
Joseph Kotarek
Branch Chief, Toxicology
Food and Drug Administration, Office of In Vitro Diagnostics and Radiological Health (OIR)
Division of Chemistry and Toxicology Devices (OHT7)
WO66 RM4643
10903 New Hampshire Ave.
Silver Spring, MD, 20993-0002
Bohdan Baczara
Deputy Director, Office of Drug and Alcohol Policy and Compliance
Office of Drug and Alcohol Policy and Compliance
U.S. Department of Transportation
1200 New Jersey Avenue, SE
Washington, DC 20590
Nomination for Membership
The DTAB membership includes individuals who represent legislatively mandated categories and serve 4-year terms. The membership criteria is described in the DTAB Charter, under the section ‘Membership and Designation’. DTAB accepts nominations on a rolling basis and will keep nomination information on file for consideration to fill any vacancies that may occur for up to 3 years. Interested persons who meet the membership criteria can send their CV/resume with a brief statement of intent, to the SAMHSA National Advisory Councils Resource Mailbox with subject line “DTAB Nomination” to: NationalAdvisoryCouncils@samhsa.hhs.gov.